The Preston Robert Tisch Brain Tumor Center
Welcome,         Profile    Billing    Logout  
 14 Trials 
17 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reardon, David A
NCT03661723: Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Completed
2
60
US
Pembrolizumab, Keytruda, Bevacizumab, Avastin, Re-irradiation
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Glioblastoma
12/21
08/24
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
CA209-324, NCT02648997: An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Active, not recruiting
2
40
US
Nivolumab - 240 mg, Opdivo, BMS-936558, ONO-4538, Ipilimumab - 1 mg/kg, BMS-734016, MDX010, MDX-CTLA4, Nivolumab - 480 mg, Nivolumab - 3 mg/kg, External Beam RT
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Meningiomas
12/24
12/25
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
NCT04826393: ASP8374 + Cemiplimab in Recurrent Glioma

Active, not recruiting
1
14
US
ASP8374, cemiplimab, Libtayo
Dana-Farber Cancer Institute, Regeneron Pharmaceuticals, Astellas Pharma Inc
Glioblastoma, Recurrent Glioblastoma
10/22
06/25
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
39
Japan, US
DSP-0390
Sumitomo Pharma America, Inc.
High Grade Glioma, Glioblastoma Multiforme
09/26
10/26
NCT02287428: Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Recruiting
1
56
US
Radiation Therapy, RT, XRT, Personalized NeoAntigen Peptides, Pembrolizumab, MK-3475, Keytruda, Temozolomide, Concurrent temozolomide; Concurrent TMZ, Adjuvant temozolomide; Adjuvant TMZ, Poly-ICLC, Hiltonol
Dana-Farber Cancer Institute, The Ben & Catherine Ivy Foundation, Accelerate Brain Cancer Cure, Merck Sharp & Dohme LLC, National Institutes of Health (NIH)
Glioblastoma
06/25
06/26
NCT05698199: Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

Active, not recruiting
1
10
US
ITI-1001
Immunomic Therapeutics, Inc.
Glioblastoma
03/26
03/26
Desjardins, Annick
DERIVe, NCT03688178: DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active, not recruiting
2
43
US
Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Temodar, TMZ, Temodal, Varlilumab, anti-CD27, Td, Tetanus-diphtheria (Td) toxoid, Td pre-conditioning, Unpulsed DCs, Unpulsed DCs pre-conditioning
Annick Desjardins, MD, Celldex Therapeutics
Glioblastoma
03/25
03/25
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
Peters, Katherine B
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
BMX-HGG, NCT02655601: Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

Active, not recruiting
2
160
US
BMX-001, manganese butoxyethyl pyridyl porphyrin, Radiation Therapy, Temozolomide, TMZ
BioMimetix JV, LLC, Duke Cancer Institute, National Cancer Institute (NCI)
High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
08/23
12/24
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
39
Japan, US
DSP-0390
Sumitomo Pharma America, Inc.
High Grade Glioma, Glioblastoma Multiforme
09/26
10/26
ViCToRy, NCT05609994: Vorasidenib in Combination with Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Not yet recruiting
1
48
US
PEPIDH1M vaccine + vorasidenib
Katy Peters, MD, PhD, Servier
Low Grade Glioma of Brain
08/27
08/29
SPiRiT, NCT04567251: Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy

Terminated
N/A
5
US
Namzaric®, Placebo
Duke University, Varian Medical Systems
Brain Metastases, Adult, Primary Brain Tumor, Lung Cancer
05/24
05/24
Affronti, Mary Lou
No trials found
Casarett, David
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reardon, David A
NCT03661723: Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Completed
2
60
US
Pembrolizumab, Keytruda, Bevacizumab, Avastin, Re-irradiation
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Glioblastoma
12/21
08/24
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
CA209-324, NCT02648997: An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Active, not recruiting
2
40
US
Nivolumab - 240 mg, Opdivo, BMS-936558, ONO-4538, Ipilimumab - 1 mg/kg, BMS-734016, MDX010, MDX-CTLA4, Nivolumab - 480 mg, Nivolumab - 3 mg/kg, External Beam RT
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Meningiomas
12/24
12/25
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
NCT04826393: ASP8374 + Cemiplimab in Recurrent Glioma

Active, not recruiting
1
14
US
ASP8374, cemiplimab, Libtayo
Dana-Farber Cancer Institute, Regeneron Pharmaceuticals, Astellas Pharma Inc
Glioblastoma, Recurrent Glioblastoma
10/22
06/25
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
39
Japan, US
DSP-0390
Sumitomo Pharma America, Inc.
High Grade Glioma, Glioblastoma Multiforme
09/26
10/26
NCT02287428: Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Recruiting
1
56
US
Radiation Therapy, RT, XRT, Personalized NeoAntigen Peptides, Pembrolizumab, MK-3475, Keytruda, Temozolomide, Concurrent temozolomide; Concurrent TMZ, Adjuvant temozolomide; Adjuvant TMZ, Poly-ICLC, Hiltonol
Dana-Farber Cancer Institute, The Ben & Catherine Ivy Foundation, Accelerate Brain Cancer Cure, Merck Sharp & Dohme LLC, National Institutes of Health (NIH)
Glioblastoma
06/25
06/26
NCT05698199: Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

Active, not recruiting
1
10
US
ITI-1001
Immunomic Therapeutics, Inc.
Glioblastoma
03/26
03/26
Desjardins, Annick
DERIVe, NCT03688178: DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active, not recruiting
2
43
US
Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Temodar, TMZ, Temodal, Varlilumab, anti-CD27, Td, Tetanus-diphtheria (Td) toxoid, Td pre-conditioning, Unpulsed DCs, Unpulsed DCs pre-conditioning
Annick Desjardins, MD, Celldex Therapeutics
Glioblastoma
03/25
03/25
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
Peters, Katherine B
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
BMX-HGG, NCT02655601: Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

Active, not recruiting
2
160
US
BMX-001, manganese butoxyethyl pyridyl porphyrin, Radiation Therapy, Temozolomide, TMZ
BioMimetix JV, LLC, Duke Cancer Institute, National Cancer Institute (NCI)
High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
08/23
12/24
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
39
Japan, US
DSP-0390
Sumitomo Pharma America, Inc.
High Grade Glioma, Glioblastoma Multiforme
09/26
10/26
ViCToRy, NCT05609994: Vorasidenib in Combination with Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Not yet recruiting
1
48
US
PEPIDH1M vaccine + vorasidenib
Katy Peters, MD, PhD, Servier
Low Grade Glioma of Brain
08/27
08/29
SPiRiT, NCT04567251: Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy

Terminated
N/A
5
US
Namzaric®, Placebo
Duke University, Varian Medical Systems
Brain Metastases, Adult, Primary Brain Tumor, Lung Cancer
05/24
05/24
Affronti, Mary Lou
No trials found
Casarett, David
No trials found

Download Options